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Validation of vessel size 
imaging (VsI) in high-grade 
human gliomas using magnetic 
resonance imaging, image-
guided biopsies, and quantitative 
immunohistochemistry
Ararat Chakhoyan1,2, Jingwen Yao1,2,3, Kevin Leu1,2, Whitney B. pope2, Noriko salamon2, 
William Yong4, Albert Lai5, phioanh L. Nghiemphu5, Richard G. everson  6, Robert M. prins  6, 
Linda M. Liau6, David A. Nathanson7, timothy F. Cloughesy5 & Benjamin M. ellingson1,2,3,8
to evaluate the association between a vessel size index (VsIMRI) derived from dynamic susceptibility 
contrast (DsC) perfusion imaging using a custom spin-and-gradient echo echoplanar imaging (sAGe-
epI) sequence and quantitative estimates of vessel morphometry based on immunohistochemistry 
from image-guided biopsy samples. the current study evaluated both relative cerebral blood volume 
(rCBV) and VsIMRI in eleven patients with high-grade glioma (7 WHO grade III and 4 WHO grade IV). 
Following 26 MRI-guided glioma biopsies in these 11 patients, we evaluated tissue morphometry, 
including vessel density and average radius, using an automated procedure based on the endothelial 
cell marker CD31 to highlight tumor vasculature. Measures of rCBV and VSIMRI were then compared 
to histological measures. We demonstrate good agreement between VsI measured by MRI and 
histology; VsIMRI = 13.67 μm and VsIHistology = 12.60 μm, with slight overestimation of VsIMRI in grade 
III patients compared to histology. rCBV showed a moderate but significant correlation with vessel 
density (r = 0.42, p = 0.03), and a correlation was also observed between VSIMRI and VsIHistology (r = 0.49, 
p = 0.01). The current study supports the hypothesis that vessel size measures using MRI accurately 
reflect vessel caliber within high-grade gliomas, while traditional measures of rCBV are correlated with 
vessel density and not vessel caliber.
Neovascularization in gliomas plays an important role in response to anti-tumor strategies1,2. Various signaling 
pathways regulate this complex mechanism, including vascular co-option, angiogenesis, vascular mimicry, and 
endothelial cell trans-differentiation3,4. It is known that this tumor vasculature is functionally and morphologi-
cally abnormal5. The quantification of abnormal vessels on histology is a standard indicator of poor outcome for 
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glioma patients6–8. Using magnetic resonance imaging (MRI), several methods have been proposed that yield 
physiologic information about tumor vasculature, including blood flow and volume9,10. Theoretical Monte-Carlo 
simulations have suggested that T2- and T2*-weighted images acquired during dynamic susceptibility contrast 
(DSC) perfusion imaging are sensitive to microvasculature and larger vessels, respectively11,12, by exploiting the 
differences in transverse relaxation rates R2* and R2 during the passage of contrast bolus through the vascu-
lature13. This effect observed in small vessels is related to the magnitude of water diffusion, which is equiva-
lent to the local susceptibility gradient. When the vascular bed is quantified with spin-echo (SE) sequence, the 
blood flow and volume are capillary weighted with a radius lower than 10 μm13, while with gradient-echo (GE) 
sequence, the hemodynamic parameters are weighted to total vessels of all size14. In this way, separate or simul-
taneous acquisitions of SE and GE parameters have been speculated to be useful in more functional information 
of blood vessels architecture and its oxygenation15–18. For example, the ratio of peak ΔR2*/ΔR2 has been shown 
to correlate with histologically derived measures of vessel size in a preclinical C6 glioma xenograft model14. This 
promising preliminary evidence suggesting a close link between the average vessel size index derived from MRI 
(VSIMRI) and histology (VSIHistology) using preclinical models16,19.
A separate model for estimating vessel size was established by Kiselev et al.17,20 and incorporates measures of 
both cerebral blood volume and water diffusivity. In this model, the proportionality constant to scale differences 
between MRI and histology has not been thoroughly validated17. Additionally, in the previous publications, the 
normalized rCBV was set generically to 6%, which represents an extreme physiological conditions21. Recently, a 
single study involving glioma patients confirmed the association between this model and vascular morphometry 
using CD34 endothelial cell marker expression22; however, despite the high number of patients and biopsy sam-
ples in each individual patient, this study reported very few identifiable vessels (~10 per sample) in some glioma 
patients, likely related to the small biopsy size (1–1.5 mm in diameter).
In this current work, we quantified relative cerebral blood volume (rCBV) and VSIMRI using a 
spin-and-gradient echo echoplanar imaging (SAGE-EPI) sequence during DSC perfusion MRI in patients with 
high-grade gliomas. The correlation between VSIMRI and rCBV with vessel density and caliber from image-guided 
biopsies were examined after staining with endothelial cell marker, CD31, chosen as a specific marker of undif-
ferentiated and differentiated microvasculature23,24. We hypothesized that Kiselev’s model, which provide several 
corrections (both diffusion and perfusion components) to estimate vessel size, would be strongly associated with 
VSIHistology.
Results
Typical example of T2w-FLAIR, post-contrast T1w, ADC, rCBV, VSI images as well as CD31 staining of 
high-grade glioma patients are shown in Fig. 1. The first patient, bearing an anaplastic oligodendroglioma lesion 
in the left frontal lobe, illustrated a lesion with hyperintensities on T2w-FLAIR images, increased ADC and rCBV 
as compared to corresponding NAWM (Fig. 1, upper). In contrast, VSIMRI maps showed potential hyper-dense 
and large vessels in the edges of the lesion as demonstrated with targets overlaid on VSI maps (rectangles) and 
confirmed with CD31 staining. Patient B, harbored a glioblastoma in left parietal lobe (Fig. 1, bottom). This 
patient has a heterogeneous ring-enhancing lesion with perilesional edema, elevated ADC within the area of 
edema, increased rCBV in the posterior part of the tumor with increased and spatially heterogeneous measures of 
VSIMRI. As confirmed with MRI and histology, high-grade gliomas patients demonstrate intra-tumoral vascular 
heterogeneity (CD31 staining) as highlighted by different targets from each patient.
We next assessed for each biopsy region, histological and MRI-derived features. From three-dimensional, 
5 mm radius biopsy targets, we found a median number of vessel of 90 [interquartile range = 64.6–117.7], a 
median density of 40.6 per mm2 [interquartile range = 29.8–78.6 per mm2] and a median vessel diameter of 12.6 
[interquartile range = 10.5–14.1 μm]. A median ADC of 1.30 μm2/ms [interquartile range = 1.05–1.63 μm2/ms] 
was measured within 5 mm biopsy targets, with a median rCBV of 1.39 [interquartile range = 1.00–2.36] and a 
median VSI of 13.6 μm2 [interquartile range = 11.98–15.06 μm2/ms].
Bland-Altman plot (Fig. 2A) suggests a significant difference between VSI measures between MRI and his-
tology. Mean difference between MRI and histology was −1.13 μm (p = 0.03, Student’s t-test) with 1.96 standard 
deviation values of the differences ranged from −0.41 μm to −2.22 μm for respectively, upper and lower limits. 
Black arrows in Fig. 2 indicate biopsy targets in WHO III gliomas where VSIMRI overestimated vessel caliber 
compared with histology.
When directly comparing MR-based perfusion measures with histology (Fig. 3A–D), MRI-derived rCBV 
showed a moderate, but statistically significant correlation with histology-derived estimates of vessel density 
(r = 0.42, p = 0.032, Fig. 3A), but not with vessel caliber (r = −0.03, p = 0.874, Fig. 3B). Consistent with our orig-
inal hypotheses, VSIMRI was significantly correlated with vessel caliber (r = 0.49, p = 0.010, Fig. 3D), but was not 
correlated with vessel density obtained from histology (r = −0.01, p = 0.942, Fig. 3C).
Discussion
The current study supports the hypothesis that VSI measured using MRI is highly correlated with the actual vessel 
caliber in underlying tumor tissue within high-grade gliomas. Additionally, the current study also supports the 
notion that rCBV measures from MRI correlated with vessel density within the tumor.
There have been several MRI based studies demonstrated the feasibility of VSI or similar measurements. 
While early studies by Donahue et al.25 and Schmainda et al.26 have demonstrated the clinical feasibility of meas-
ures of mean vessel diameter (mVD), VSI measures that take into account both rCBV and ADC, which can influ-
ence vessel size measurements, have only been thoroughly evaluated orthotopic brain tumor models, which found 
with good quantitative agreement of histology19,27. However, all these studies have used high field MRI (up to 
4.7 T) with potential imperfections of main B0 and transmit B1 magnetic fields, which should be considered28 for 
the appropriate quantification ΔR2*, ΔR2 and finally VSI. A recent publication using Tropès model showed that, 
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with high-field MRI (7 T), VSI measurements tend to overestimate as compared to two-photon laser scanning 
microscopy29. This observation may be due to underestimation of blood volume in the tumor and/or heterogene-
ous distribution of vessel radii.
Recently, the Kiselev model VSIMRI has been reported with adjusted rCBV values for healthy tissue to more 
typical values for blood volume (3.2%)22. The former study also compared histological findings (vessel diameter) 
with MRI results (rCBV and VSI). With an averaged rCBV of 5.99% (uncorrected for contrast leakage); an ADC 
of 1.02 μm/ms, authors reported an average VSI of 67.13 μm in high-grade glioma, which is two times higher than 
what they reported for mean vessel diameter (31 μm) but has good agreement with maximum vessel diameter 
(69.8 μm). However, the tissue targeting protocol of that study may be biased, as for 4 glioblastoma patients, 
authors reported less than 6 detected vessels with CD34 endothelial marker. This marker is known to be specific 
for differentiated, well-formed vessels (including normal vessels)30 which makes results difficult to interpret.
With the same range of healthy tissue blood volume, 3%, Xu et al.31, reported an average VSI of 13.8 μm in 
gray matter and 13.1 μm in white matter. These results of healthy tissues are correlates well with vessel radius 
values reported by Christen et al.30, (12.6 ± 2.4 μm with 3.1% of CBV in gray matter). Note that in our study, the 
rCBV is only normalized to contralateral NAWM and the average rCBV was 0.96, which in turns, results to an 
average VSIMRI of normal appearing brain 4.51 μm (results not shown). Additionally, a study of confocal laser 
microscopy reports an average vessel diameter of human cortex lower than MRI approaches; 7.82 ± 3.52 μm31, 
which is in accord to other mammalian neocortex vascular diameter (e.g. cat and rat; ranged from 4.2 to 7 μm), 
reviewed by Pawlik et al.32. Indeed, the fact that VSIMRI correlates to VSIHistology independently of vessel density is 
very promising; however, some overestimation is reported in our current study, especially in the WHO grade III 
patients and in preclinical studies15,16. This overestimation from VSIMRI is consistent with results of Kellner et al.22, 
Figure 1. Two representative high-grade glioma patients are reported with their respective biopsy targets. T2w-
FLAIR (upper) or post-contrast T1w (bottom) images were used for anatomical reference in tissue sampling in 
various tumor grades. ADC, rCBV and VSIMRI maps are shown for each patient. The first patient (upper) has a 
WHO grade III, Anaplastic Oligodendroglioma. The brain lesion is located in the left frontal lobe. The second 
patient (bottom) is a WHO Grade IV glioblastoma with a brain lesion located in the left parietal lobe. An 
elevated ADC and rCBV showed in both patients within tumor areas. Glioblastoma patient show an increased 
heterogeneity of vessel size within and around enhancing areas. Examples of tissue slides with stained CD31 
positive vessels for each representative target. As observed with VSIMRI, in both grade III and IV, CD31 positive 
vessels are present with spatial heterogeneity in terms of density and morphometry.
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Figure 2. Bland-Altman plot represents potential bias of agreement between these two techniques. A number 
of points display higher difference between VSIMRI and VSIHistology, especially in grade III (black arrows). Filled 
and unfilled circles presenting targets from grade III and grade IV, respectively.
Figure 3. Linear correlation was performed between rCBV, VSIMRI and their corresponding histology value; 
vessel density and vessel caliber (VSIHistology). Positive linear correlation was found between rCBV vs. vessel 
density (A, r = 0.42, p = 0.032) as well as between VSIMRI and vessel caliber (D, r = 0.49, p = 0.010). However, 
no direct relationship was observed between rCBV and vessel caliber (B). VSIMRI measures are independent of 
vessel density (C). The filled and unfilled circles presenting targets from grade III and grade IV, respectively.
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as well as from a rodent study19, and occurs especially in small vessel sizes. The following imperfection could be 
overcome by assessing VSIMRI with more flexible topological models including vessel length, radius, and vessel 
orientation angles33. Additionally, our observations regarding the association between rCBV and vessel density 
appear consistent with previously reported results from tumor bulk34; however, tumor vessel size heterogeneity 
often influences the reliability of rCBV estimates in comparison with histology35.
There were certain limitations of our experimental setup that should be addressed. First, the limited spa-
tial resolution and the registration of lower-resolution SAGE-EPI to high-resolution 3D-T1w images may have 
resulted in potential bias. It is important to note that precise targeting of brain tissue during biopsy is a significant 
technical challenge, as inherent changes in the brain position during craniotomy may occur, which could directly 
affect accurate MRI-guided sampling of tumor specimens. Additionally, the use of rCBV as a normalized approx-
imation of rCBV is another limitation of VSI modeling which could have led to inaccuracies. Also, the specificity 
of VSIMRI to perfused vessels can also result in discordance between VSI measurements and histology. Moreover, 
the “delta” term that describes the residual signal differences from imperfectly matched slice profiles may vary 
over time and may be dependent on the radiofrequency architecture and other details. However, this did not 
vary more than 3–6% across patients over time in our study (results not shown), so it likely did not influence our 
results. Finally, contrast-to-noise (CNR) ratio over time may have been affected by use of a single dose of contrast 
agent, particularly for estimation of R2, so this should also be recognized.
In summary, the current study estimated VSI with SAGE-EPI in high-grade glioma patients and correlated 
this measurement with histological characteristics of the vessel architecture. Results demonstrated that VSI meas-
ured with MRI is correlated with vascular caliber, while vessel density is mostly linked to measures of rCBV.
Material and Methods
patients. This study was performed in accordance with the Health Insurance Portability and Accountability 
Act (HIPAA), and all patients provided signed, informed written consent for all experimental protocols used in 
the current, institutional review board approved study (UCLA Medical IRB 2, #14-001261). Eleven patients with 
histologically confirmed high-grade glioma (7 WHO grade III [4 de novo and 3 at first recurrence] and 4 WHO 
grade IV glioblastoma [2 de novo and 2 at first recurrence]) have been enrolled in this retrospective study. From 4 
de novo grade III patients, 3 were anaplastic oligodendroglioma and one diffuse astrocytoma (IDH mutant). From 
remaining 3 recurrent grade III patients, 2 were anaplastic gangliogliomas and one anaplastic astrocytoma. For 
5 enrolled recurrent patients, 4 received standard craniotomy, followed by chemoradiation prior to the second 
craniotomy. One anaplastic oligodendroglioma received only craniotomy in 2009 and image-guided biopsy was 
performed in 2015. Of the 11 enrolled patients (9 men and 2 woman), the median age was 50.8 years ranged from 
28.5 to 67.9 years. Both MRI and neuropathology specimens were obtained and analyzed with respect to local 
ethical committee approval. In total, 26 MRI-based targets were biopsied and analyzed.
Magnetic Resonance Imaging. All MRI images were acquired using a 3 Tesla MRI system (Siemens; 
Erlangen, Germany) in compliance with the international standardized brain tumor imaging protocol (BTIP)36. 
Briefly, 1 mm isotropic, 3D MPRAGE T1-weighted images were acquired prior to contrast injection, along 
with axial T2-weighted images and T2-weighted fluid attenuation inversion recovery (FLAIR) images. Axial 
diffusion-weighted imaging (DWI) was performed using a single-shot echo-planar imaging with three b values 
(0, 500 and 1000 sec/mm2) to compute the apparent diffusion coefficient (ADC). T2-, T2-weighted FLAIR, and 
DWI were all collected with 3-mm slice thickness and no interslice gap.
VSIMRI and rCBV were calculated by acquiring dynamic SAGE-EPI data during contrast injection. A pre-dose 
0.025 mmol/kg of Gd-DTPA was first administrated reduce contrast extravasation, followed by a bolus dose 
of 0.075 mmol/kg. The SAGE-EPI readout consisted of two gradient echoes (TE1 = 14.0 ms; TE2 = 34.1 ms), an 
asymmetric spin echo (TE3 = 58.0 ms) and a spin echo (TE4 = 92.4 ms) EPI train with GRAPPA acceleration fac-
tor of 3. The repetition time was 2000 ms with a slice thickness of 5 mm and no additional spacing between slices. 
The resolution was set to 1.875 × 1.875 mm with a total matrix size of 240 × 218 mm. A total of 90 repetitions 
were obtained over 19 axial slices. Following DSC perfusion acquisition, a parameter matched, 1-mm isotropic, 
post-contrast 3D MPRAGE T1-weighted dataset was acquired according to BTIP.
MRI post-processing. Dynamic susceptibility contrast based relative cerebral blood volume (rCBV) maps 
were calculated using an in-house bi-directional contrast agent leakage correction algorithm that accounts for 
both contrast flux out of and into the vasculature37. Normalization of rCBV maps was performed by comparison 
to contralateral normal appearing white matter (NAWM).
Estimation of VSIMRI was based on the Kiselev model17, which is built upon on the basis of Tropès model15 
with additional consideration for rCBV values and use the ratio of ΔR2*/ΔR2 as a result of average vessel size 
index, expressed in μm:
= . ⋅



Δ
Δ



μ
⁎RVSI 0 867(rCBV ADC)
R (1)
m
1/2 2
2
3/2
where ∆ ⁎R2  and ∆R2 represents the maximum changes in the transverse relaxation rates obtained from solving 
the following linear equation38:
= −A Y S (2)1
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where Sn is signal magnitude for the nth echo and δ is the differences in residual signal differences introduced from 
imperfectly matched slice profiles. Those discordances are related to the echo trains, before and after refocusing 
pulse39.
Image registration. All images (T2w, FLAIR, ADC, rCBV, and VSIMRI) were registered to 1-mm isotropic 
post-contrast T1-weighted images using a 12-degree-of-freedom, automated linear registration tool using a 
correlation ratio cost function (FSL-FLIRT, http://www.fmrib.ox.ac.uk/fsl/). All registered maps were visually 
inspected and, if necessary, manually corrected in the event of misregistration.
Image-guided biopsy and Immunohistochemistry. After image acquisition, one to three (5 mm radius) 
targets were identified on post-contrast T1w and/or fused T2w-FLAIR images within contrast-enhancing (tumor 
core) and non-enhancing tumor regions, respectively. These targets were loaded into BrainLab Neuronavigation 
software (BrainLab AG, Munich, Germany). Following target identification, a critical review was performed by 
the primary neurosurgeon to make sure that targets were within the final resection volume, did not affect brain 
eloquent areas (assessed by blood level dependent contrast (BOLD) activation maps) and were not within the 
main trajectory of large white matter tracts (assessed by diffusion tensor imaging).
Following image-guided resection, biopsy samples were transferred to the Department of Pathology & 
Laboratory Medicine for immunohistochemistry (IHC) staining. IHC using an antibody against the endothe-
lial cell marker CD31 has been chosen. Staining was performed on 4 μm paraffin-embedded sections after ini-
tial dewaxing with xylene and rehydration through graded ethanol, followed by antigen retrieval with a pH 6.0 
Antigen Retrival Solution (Biocare Medical) in a Decloaking pressure cooker at 95 °C for 40 min. Tissue sections 
were then treated with 3% hydrogen peroxide (LOT 161509; Fisher Chemical) and with Background Sniper 
(Biocare Medical, Concord, CA, USA) to reduce nonspecific background staining. All slides were then incubated 
at room temperature for 80 min with ready to use primary antibody for CD31 (Biocare, 090215) followed by 
detection with the MACH 4 Mouse HRP- Polymer Detection kit (Biocare Medical). VECTOR NovaRED (SK-
4800; Vector Laboratories, Inc.) was applied as chromogen.
Segmentation of blood vessels from CD31 staining and quantification of VSIHistology. Segmentation 
of CD31 was performed on 2D stained slices based on the CAIMAN algorithm40. Briefly, the algorithm exploits the 
distinctive hues of stained vascular endothelial cells, cell nuclei and background. A region-growing algorithm using the 
seeds created with the previous step and a 3D Hue, Saturation, Value (HSV) color model. Three major morphological 
tasks were then performed: (1) joining separate objects that were likely to belong to a single vessel; (2) closing objects 
that had a narrow gap around their periphery; and (3) splitting objects with multiple lumens into individual vessels. A 
hole fill was performed to include vessel lumen in the calculation of vessel radius. Manual correction was performed 
on the stained slices with obvious errors. A total of 3 regions of interest were selected for each target and the average 
quantification of these 3 values was attributed to each target.
After segmentation, vessel density (number divided by the total area of the sample) was computed and 
expressed in N/mm2. Quantification of VSIHistology on the stained slides were then performed following a pre-
viously described model16 (assuming vessels are randomly oriented, continuous cylinders with different radii):
=
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where n r( )i  is the number of vessels with radius r. Final results are expressed in μm.
statistical analyses. A nonparametric Wilcoxon-Mann-Whitney test was used to assess potential statistical 
differences in both WHO grade III and IV for all MRI and histology-derived parameters. Regression was per-
formed to assess the degree of agreement between MRI (rCBV and VSIMRI) and histology (density and VSIHistology). 
An alternative analysis of potential bias determination between these two techniques (VSIMRI vs. VSIHistology) was 
performed using a Bland-Altman test. The difference between VSIMRI vs. VSIHistology was assessed using Student’s 
t-test, after checking the normality of each distribution using a Shapiro-Wilk test41,42.
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